Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

FTSE rallies as EU membership 'Remain' camp regains ground

Published 20/06/2016, 09:39
Updated 20/06/2016, 09:50
© Reuters. A worker shelters from the rain as he passes the London Stock Exchange in the City of London

By Kit Rees

LONDON (Reuters) - UK shares paced by banks and housebuilding rose on Monday, boosted by polls suggesting the campaign for Britain to remain in the European Union was regaining a narrow edge over the "Out" camp.

Britain's blue chip FTSE 100 index (FTSE) rose 2 percent to 6,138.78 points by 0909 BST, extending Friday's 1.2 percent gain.

Two opinion polls published on Saturday showed that the campaign to keep Britain in the European Union ahead of its June 23 referendum had regained its lead, while a third poll also showed momentum for an "In" vote.

The overall picture, however, remains one of an evenly split electorate.

"The risk-off mood of last week which was fading on Friday has turned decisively this morning and ... this (could) extend into the rest of the week provided that the polls continue to point towards 'Remain'," Chris Beauchamp, senior market analyst at IG, said.

Shares in domestically-focused companies, seen as sensitive to the outcome of Britain's June 23 referendum on its EU membership, rallied, with banks Royal Bank of Scotland (L:RBS), Lloyds (L:LLOY) and Barclays (L:BARC) all jumping between 4.6 percent and 6.8 percent.

Housebuilders Taylor Wimpey (L:TW), Barratt Developments (L:BDEV), Berkeley Group (L:BKGH) and Persimmon (L:PERS) also rose, gaining between 4.3 percent to over 6 percent.

Precious metals miners Rangold Resources (L:RRS) and Fresnillo (L:FRES) were the only fallers on the blue chip index, down 2.6 and 0.8 percent respectively as investors dumped perceived safe-haven assets and the price of gold fell.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Among the mid-caps, however, Circassia Pharmaceuticals (L:CIRCI) plunged over 65 percent after a cat allergy treatment failed in a late-stage trial due to a marked placebo effect.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.